p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer
Open Access
- 1 January 2000
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 82 (1), 136-141
- https://doi.org/10.1054/bjoc.1999.0890
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers.1996
- The clinical value of urinary cytology: 12 years of experience with 615 patients.Journal of Clinical Pathology, 1995
- Identification of H-ras Mutations in Urine Sediments Complements Cytology in the Detection of Bladder TumorsJNCI Journal of the National Cancer Institute, 1995
- Screening of human bladder tumors and urine sediments for the presence of H‐ras mutationsInternational Journal of Cancer, 1993
- p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.1993
- Increased accumulation of p53 protein in cisplatin-resistant ovarian cell linesInternational Journal of Cancer, 1993
- Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumors with mixed cell populations.1993
- The Role of Flow Cytometry in the Management of Bladder CancerHematology/Oncology Clinics of North America, 1992
- An lmproved method for directly sequencing PCR-amplified material using dimethyl sulphoxideNucleic Acids Research, 1989
- Flow Cytometry and Cytology as Response Indicators to M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin)Journal of Urology, 1988